PHI raises 4.8 million USD

In a public offering PHI raises 40 million Swedish kronor (4.8 million USD). The raised funds will allow PHI to further address customer needs by developing the company organization and by expanding the HoloMonitor® product line.

PHI is publically traded on AktieTorget and leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the Company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains.

Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.